Ionis Pharmaceuticals 10K 2013 Annual report | IONS Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman V good

New words: abdominal, Abraxane, absolute, abuse, ACD, adipose, Alport, amplification, androgen, antiviral, apatorsen, apo, APOCIIIRx, Argentina, Breaux, carcinoma, Castleman, CEO, Chiriboga, chosen, chylomicronemia, cisplatin, civil, Claudia, colistin, contending, Cornerstone, Corrupt, creation, criminal, CTG, custodian, debarment, deprivation, diflunisal, disabling, displace, Distinguished, Dohme, dropped, enterobacteriaceae, enzalutamide, evolved, export, FCPA, FCS, fish, Forum, fraud, gemcitabine, gland, guideline, Hammersmith, HCC, HDL, hepatocellular, HFMSE, HTT, hyperlipidemia, hypoglycemic, Icon, immunosuppressive, induced, infertility, insensitivity, justify, Kathy, Korea, lifespan, Loscalzo, maker, MDR, Merck, Mexico, modality, monoclonal, mutation, niacin, noninfringement, Northern, nosocomial, official, older, ordinary, outlining, oxidized, Pacific, palliative, patisiran, permanent, Physical, pilot, pneumonia, point, poised, pradigastat, predominantly, prepaid, proatherogenic, proceeding, prohibit, proinflammatory, proliferation, RA, Raal, Rainier, recurrent, region, rejected, rendered, reoccur, repeat, respond, rest, restructuring, score, Sharp, shipped, shutdown, shuttle, SMNRx, sofosbuvir, spleen, Spruce, Suboptimal, Swoboda, tetramer, Toronto, training, unable, underwriting, Unvested, Vyndaqel, Wyeth, Zytiga

Removed: agreeing, AI, alternate, America, anniversary, Arca, attributable, capitalization, concentration, Crohn, derived, display, double, evenly, exchangeable, feasibility, gap, monotherapy, moved, NYSE, organ, output, pharmacokinetic, preparing, properly, reclassification, recouped, refractory, requirement, retrospectively, route, simplified, splice, stable, varying, vivo, worse

Ionis Pharmaceuticals (IONS) 10-K2013 FY Annual report

Content analysis